Loading
Sarcoma oncologist who led ANNOUNCE and the pexidartinib trial that produced the first drug for tenosynovial giant cell tumour.
William Tap led ANNOUNCE, the phase 3 trial that found olaratumab did not improve survival in soft-tissue sarcoma despite a striking phase 2 result, a widely cited cautionary tale for accelerated approval, and ENLIVEN, which won pexidartinib approval for tenosynovial giant cell tumour. He chairs the Alliance sarcoma committee and leads sarcoma medical oncology at MSKCC.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares ANNOUNCE, Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.